AstraZeneca's Farxiga could be on course for another ... decline of at least 50% sustained decline in estimated glomerular filtration rate, onset of end stage kidney disease or cardiovascular ...

AstraZeneca's SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly's ...